NCT06614140 — Seqker Biosciences neoantigen vaccine trial
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
Registry record
| Registry ID | NCT06614140 ↗ |
|---|---|
| Lead sponsor | Seqker Biosciences, Inc. |
| Collaborators | — |
| Phase | Phase 1/2 |
| Status | Completed |
| Indication | Cancer, Solid Tumor, Adult |
| Enrollment | 8 participants |
| Start date | 2022-11-24 |
| Primary completion | 2025-08-15 |
| Last registry update | 24 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06614140), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT06614140?
NCT06614140 (Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Seqker Biosciences, Inc..
Is NCT06614140 recruiting?
As of the 2026-07-24 registry update, NCT06614140 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06614140?
The lead sponsor is Seqker Biosciences, Inc..
What condition does NCT06614140 study?
The registered conditions are Cancer, Solid Tumor, Adult. Primary completion is listed as 2025-08-15.
Are results available for NCT06614140?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06614140.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.